Opioid rescue demand There is a clear market need for abuse-deterrent and overdose-reversal therapies targeting synthetic opioids like fentanyl, with Elysium’s SOOPR platform positioning to address long-acting rescue and effectiveness gaps.

Oral overdose protection Opportunity to partner with pharmaceutical manufacturers of oral opioids or pain management regimens to license O2P or XpiRx technologies to reduce abuse potential and accidental overdoses in prescribed products.

Strategic partnerships Leverage non-dilutive funding history and recent $7.5M SAFE round to attract co-development or grant-enabled collaborations with biotech, pharma, and government programs focused on opioid crisis mitigation.

Diversified pipeline Position products across multiple unmet needs within the opioid crisis, enabling cross-sell opportunities to partners seeking portfolio expansion into overdose prevention, reversal, and abuse-resistance across different formulations.

Regulatory and IP moat Emphasize strong US and international patents and FDA-aligned data as a differentiator when engaging potential licensees or collaborators, signaling defensible tech with expedited path to near-term product candidates.